Cansortium (XCNQ:TIUM.U) EV-to-Revenue : 1.40 (As of May. 28, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Cansortium EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Cansortium's enterprise value is $136.57 Mil. Cansortium's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $97.29 Mil. Therefore, Cansortium's EV-to-Revenue for today is 1.40.

The historical rank and industry rank for Cansortium's EV-to-Revenue or its related term are showing as below:

XCNQ:TIUM.U' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.18 Med: 3.79 Max: 25.96
Current: 1.4

During the past 6 years, the highest EV-to-Revenue of Cansortium was 25.96. The lowest was 1.18. And the median was 3.79.

XCNQ:TIUM.U's EV-to-Revenue is ranked better than
69.6% of 1023 companies
in the Drug Manufacturers industry
Industry Median: 2.29 vs XCNQ:TIUM.U: 1.40

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-28), Cansortium's stock price is $0.165. Cansortium's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.28. Therefore, Cansortium's PS Ratio for today is 0.59.

Cansortium EV-to-Revenue Historical Data

The historical data trend for Cansortium's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cansortium EV-to-Revenue Chart

Cansortium Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

3.70

3.11

3.59

1.30

1.19

Cansortium Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															1.30	1.19	1.22	1.16	1.19

Competitive Comparison of Cansortium's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Cansortium's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cansortium's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cansortium's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cansortium's EV-to-Revenue falls into.

Cansortium EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Cansortium's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	136.567	/	97.29
	=	1.40

Cansortium's current Enterprise Value is $136.57 Mil.
Cansortium's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $97.29 Mil.

Cansortium (XCNQ:TIUM.U) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Cansortium's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.165	/	0.278
	=	0.59

Cansortium's share price for today is $0.165.
Cansortium's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.28.

Cansortium EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cansortium's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Cansortium (XCNQ:TIUM.U) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cansortium Inc (XCNQ:TIUM.U) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

CNTMF:USA

Address

82 North East 26th Street, Suite 110, Miami, FL, USA, 33137

Website

https://getfluent.com

Cansortium Inc is licensed to produce and sell medical cannabis in Florida and Texas and is licensed to sell medical cannabis in Pennsylvania. Its medical cannabis products are offered in oral drops, capsules, topicals, syringes, dried flowers, pre-rolls, cartridges, and edibles. All of the company's products are marketed under the Fluent brand name. In Pennsylvania, the company's product portfolio is comprised of a variety of third-party branded medical cannabis products.

Cansortium (XCNQ:TIUM.U) Headlines

No Headlines